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Objectives: EUnetHTA WP 7 (Strand B) aimed to promote sharing information on new
and emerging technologies. The task was to develop a prototype of a newsletter and pilot
the processes of production.
Methods: The EuroScan database served as information source on pertinent
technologies. To prioritize, a set of criteria for scoring the potential impact and for
selecting the technologies for articles was applied and a pilot newsletter was produced.
Results: Being objective and transparent about the content of a newsletter required a
method for prioritizing health technologies. Using significance criteria, members of the
prioritization panel selected twelve technologies for articles of different length and depth.
Potential recipients, surveyed on relevance, content, timeliness, and readability
responded mostly positive, but requested more information on cost effectiveness and
criticized timeliness.
Conclusions: Dissemination of an EU-wide newsletter would be feasible, but
time-consuming. Although a newsletter appears to fulfill a need for information on
emerging and new health technologies, it is not considered the right tool to avoid
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duplication of effort in the present international constellation of horizon scanning for new
health technologies. Other options will be pursued as part of future collaborative actions,
for example, a core set of early awareness information, or an on-demand electronic
information system.
Keywords: Health technology assessment, Horizon scanning, Early warning
Early identification and monitoring of new and emerging
health technologies has been of interest in health tech-
nology assessment (HTA) agencies for many years (12–
14). The agencies involved have developed programs under
different synonyms, for example, horizon scanning, early
warning, emerging technology assessment, alert, and early
awareness and alert systems (EAASs). In 1998, EuroScan
(international information network on new and emerging
health technologies), a collaborative network of international
(not only European, 19 agencies in 2008) agencies conduct-
ing horizon scanning, was founded (2;7). Some agencies
publish outputs as short (4–6 pages) reports—Technology
Briefings (National Horizon Scanning Centre, England),
TechNotes (former Alberta Heritage Foundation for Medical
Research, Canada), Alerts (Swedish Council on Technology
Assessment in Health Care, Sweden), Emerging Technology
Bulletins (Canadian Agency for Drugs and Technologies in
Health, Canada)—on their respective Web sites and actively
distribute them to a small number of regional and national
decision makers.
Western healthcare systems are confronted with a rising
number of new technologies. In globalized markets, many
of these systems must make decisions on the managed in-
troduction or reimbursement of the same technologies. Work
Package 7 (WP7) of the European network for Health Tech-
nology Assessment (EUnetHTA) (10;11) aimed to contribute
toward avoiding duplication by making the information gath-
ered in formal horizon scanning activities available to a wider
audience. WP7 would do this by “disseminating information
on early identification and assessment activities” (17) be-
yond regional or national decision makers and to countries
within the European Union (EU) that had not established
systems for identifying new and emerging health technolo-
gies. This idea is not new. Conclusions from a workshop
(Scanning the Horizon for Emerging Health Technology)
in 1997 strongly recommended that agencies working with
early warning should collaborate and coordinate, with a pri-
mary focus on sharing information at different levels (2).
Wider dissemination of information on new and emerging
technologies was revisited in 2001 by the European Col-
laboration for Health Technology Assessment/ Assessment
of Health Interventions (ECHTA/ECAHI) project, funded
by the European Commission (9). Consolidation of the pi-
lot, electronic EuroScan database was recommended, with
access being limited to EuroScan members in the short to
medium term. In 2005 (15), a status report from EuroScan
listed potential projects, for example, a newsletter or digest
for nonmembers, producing reports with a shared focus, and
widening nonmember access to the early warning database.
The “core early assessment” idea was also raised, further
indicating the potential for more exchange of information
relative to the current situation.
AIMS AND OBJECTIVE
The task of EUnetHTA Work Package 7, Strand B (WP7B)
was to develop a European-wide newsletter on new and
emerging health technologies and to provide information
on costly, high-volume, rapidly developing technologies that
could significantly impact health care. This newsletter should
contain information on the technology itself, on the nature
of the condition (burden of disease), on the prevalence of the
disease, and on standard treatments and their effectiveness.
Because this newsletter would be highly visible and could
potentially impact on setting the agenda and discussing new
and emerging technologies throughout Europe, the underly-
ing processes of its production were required to be transpar-
ent and reproducible. This particularly applied to the meth-
ods used in selecting the technologies to be included in the
newsletter.
This article: (i) describes the general principles for iden-
tifying, filtering, and prioritizing new and emerging health
technologies; (ii) describes the process and method under-
lying how the EuroScan database was used to develop a
newsletter and how an international panel selected technolo-
gies from this database for the newsletter; and (iii) discusses
issues related to future priority setting exercises, information
sharing in this field, and methodological issues concerning
the choices made.
STRUCTURE AND METHODS
General Principles for Identification and
Priority Setting
The horizon scanning process aims to inform about develop-
ing technologies that may significantly impact health care.
Briefly, the process consists of five sequenced, main com-
ponents (15): (i) Identification, (ii) prioritization, (iii) early
assessment and impact prediction, (iv) dissemination, and (v)
monitoring. To report on selecting topics for the information
service (newsletter) and making this process reproducible
and transparent, we describe only the first two steps (identi-
fication and prioritization) in greater detail.
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Identification. The challenge of identifying new
health technologies involves gathering information of suf-
ficient quality from a huge quantity of data (4). Many scien-
tific developments appear on the horizon, but never reach the
market stage. Others can, seemingly from nowhere, diffuse
rapidly throughout the healthcare system. Hence, identifica-
tion may be perceived as the first part of filtering before the
prioritization process.
Depending on the field of interest a broad spectrum of
identification sources must be selected and scanned regu-
larly. Some horizon scanning programs focus only on specific
medical fields or technology types (e.g., ASERNIP-
S/Australian Safety and Efficacy Register of New Interven-
tional Procedures-Surgical; LBI-HTA/Ludwig Boltzmann
Institute of Health Technology Assessment: Oncology (8)),
whereas others address the whole range of technologies and
specialties (NHSC, CADTH). To overview different iden-
tification procedures we must recognize that the diffusion
contexts for health technologies differ considerably. Some
technologies must pass regulatory hurdles, resulting in more
predictable market entry, for example, drugs that must be ap-
proved by the Food and Drug Administration (FDA) or the
European Medicines Agency (EMEA). Others, for exam-
ple, surgical procedures, generally emerge within medical
professions in more random manner without formal mar-
ket approval. Similarly the speed of diffusion varies, with
pharmaceuticals generally diffusing more rapidly than de-
vices (1). Given these different diffusion conditions, one can
assume that information sources will vary by technology
type.
A classification of health technologies (16) aims to ex-
plore the most useful sources for identifying new ones. Moni-
toring the sectors where technologies are most likely to orig-
inate, dozens of specific sources are scanned regularly for
the following: Pharmaceuticals, Diagnostic strategies, Pro-
cedures, Procedural devices, Other medical and assistive
devices, Healthcare settings or treatment delivery systems,
Information technology, and New professions.
Attempts to classify the huge number of sources offering
information on health technologies involve (most common)
categorization into primary, secondary, and tertiary sources.
Primary sources provide information from developers or
manufacturers, for example, patents, FDA licensing appli-
cations, and company Web sites. Secondary sources provide
information (mostly published) on the technology in use from
medical, financial, or social perspectives, for example, drug
information services, conference abstracts, journals, expert
groups, etc. Tertiary sources provide information from other
organizations engaged in identifying new healthcare tech-
nologies, for example, other horizon scanning products. The
separation into primary, secondary, and tertiary also high-
lights trade-offs between earlier “warning” (timeliness), vol-
ume, and greater accuracy of the information provided. For
example, the Austrian program scans sixty-three sources reg-
ularly/weekly, solely to identify drugs in oncology (8). In
other fields (e.g., telemedicine or cardiology devices) fewer
sources might be scanned less frequently.
Priority Setting. Identification reveals many of the
health technologies that appear on the horizon. The next
step is to select the technologies in which to invest further
resources (5). The general objective of priority setting in
horizon scanning is to define the potentially most significant
new and emerging technologies in which to invest scarce as-
sessment resources. Obviously, the term “most significant” is
ambiguous and requires further definition in terms of impact
on patients, health service, and/or costs. Generally, in this
stage of horizon scanning a choice will be made whether to
assess a technology or continue to monitor it.
Because the process of selecting technologies by agree-
ment (3) is susceptible to subjectivity, some tools capable
of enhancing accountability in the selection process have
been developed for the EU information service on emerg-
ing technologies. In addition to using explicit criteria, it will
be necessary to define individual criteria to improve com-
mon understanding. Another tool is a formal checklist of the
selection criteria and their indicators to assure that all cri-
teria receive equal consideration. Finally, documentation of
the decision-making process substantially enhances account-
ability and transparency.
EuroScan member agencies identify and prioritize new
and emerging health technologies as described. Members
add the health technologies they identify and prioritize to the
EuroScan database of new and emerging health technologies
and continuously update the Web-based database, adding
around 200 new entries annually (6).
Developing an EU-wide Newsletter
The EUnetHTA newsletter on high-volume, costly, and
rapidly developing new and emerging health technologies
aimed to provide information on the technologies’ early stage
of development and on their possible significant impact on
health care in the EU. Information in the newsletter was in-
tended to help decision makers better anticipate, plan, and
manage the introduction and diffusion of new health tech-
nologies. It was proposed that the newsletter would be pub-
lished quarterly, and that each issue would cover eight to
twelve technologies, providing information of various depth
and detail, depending on the results of scoring the potential
significance and impact of the respective health technology:
One type 1 technology, 3 to 4 type 2 technologies, and 4 to 7
type 3 technologies (Box 1).
To be objective and transparent about the contents of the
newsletter, a method for prioritizing health technologies was
imperative. The EuroScan secretariat at the National Horizon
Scanning Centre (NHSC) in England was actively involved in
planning and developing methods for the production of the
newsletter. All EuroScan members agreed that EuroScan’s
database of new and emerging technologies could be used as
a source of information on pertinent technologies.
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Box 1. Types of Articles Providing Different Depths of Infor-
mation
• A Type 1 “headline” technology was deemed to be the
most significant at that time given the information
available. For this technology, comprehensive
information was provided in the newsletter.
• A Type 2 technology was considered to be potentially
important given the information available. For these,
a paragraph or two was provided in the newsletter
giving basic details of the technology.
• A Type 3 technology was considered to be of lesser
importance given the information available. One to
two sentences were provided on these technologies
in the newsletter.
Initial Selection of Technologies
The EuroScan database was used to select an initial long
list of new and emerging health technologies, added to
the database in the previous 6 months (July to December
2007), for potential inclusion in the first issue of the newslet-
ter. We entered (Excel spreadsheet) the following informa-
tion on each of the technologies: Technology name, Com-
pany/Developer, Technology description, Patient indications,
Stage of development, Technology type, Technology use,
Number of patients, Cost, Existing technology, and Reason
for entry on the EuroScan database.
This information constituted Part A of the spreadsheet.
Each technology was considered: in the case of pharmaceu-
ticals, already licensed or within 6 months of approval; and
in the case of nonpharmaceuticals, already diffused in some
EU-countries (although this information was often difficult
to obtain).
The list was then edited to provide as much information
as possible to the prioritization panel. The list grouped sim-
ilar technologies so that a particular class of drug, type of
technology, or technologies aimed at the same disease group
could be compared. Particular attention was given to pro-
viding up-to-date information on the stage of development,
number of patients, and cost. This resulted in a list of 104
health technologies for the pilot issue and 73 for the pilot
first issue of the newsletter.
Significance Criteria and Scoring System
Using criteria developed by EuroScan we developed signifi-
cance criteria to be applied to each technology in the list and
a scoring system. The significance criteria were piloted and
revised following feedback from the prioritization panel after
the first round of selecting technologies to be included in the
pilot newsletter. The significance criteria shown in Table 1
constituted headings in part B of the Excel spreadsheet. Scor-
ing was linked with the response, giving a higher score to
Table 1. Scoring of Potential Impact of the Technology (Part B)
Significance criteria Answer Score
1. Is this an innovative therapy for a condition Yes 2
with no satisfactory standard treatment?
No 0
Don’t know 0
2. Is there potential for a significant health benefit to the Major 2
patient group if the technology reaches its potential?
Moderate 1
Minor 0
Uncertain 0
Unknown 0
3. Is there potential for inappropriate diffusion Major 2
(too fast or too slow) or use of the technology?
Moderate 1
Minor 0
Uncertain 0
Unknown 0
4. Is there potential for a significant cost Major 2
impact if the technology is diffuses widely?
Moderate 1
Minor 0
Uncertain 0
Unknown 0
5. Will significant service reorganization, purchase of Major 2
of equipment or staff training be required?
Moderate 1
Minor 0
Uncertain 0
Unknown 0
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Table 2. Scoring on Newsletter Details (Part C)
Question Answer Score
Do you think the technology Yes 2
should be included in the newsletter
No 0
Don’t know 0
If Yes, which type of Type 1 3
newsletter article should this be?
Type 2 2
Type 3 1
responses that indicated a greater impact and a zero score to
responses that indicated an uncertain or low impact.
Members of the prioritization panel could also express
their overall opinion of the technology—based on informa-
tion in the spreadsheet and their responses regarding impact
of the technology—by saying if the technology should be in-
cluded and at what level, given the aims of the newsletter. Part
C of the spreadsheet presents these questions, and Table 2
shows the scoring.
Prioritizing Technologies for Inclusion in
the Newsletter
A prioritization panel comprised of EuroScan members
and representatives from EUnetHTA WP7 was established
(Box 2). Members of the panel were all involved in early
awareness and alert activities, so they had skills in predict-
ing the impact of a technology with limited information as
provided in the spreadsheet. Panel members were sent the
spreadsheet of technologies and asked to independently con-
sider each technology against the significance criteria. They
were also sent instructions for using the spreadsheet and def-
initions of the terms used.
Box 2. Prioritization Panel and Editorial Board
Prioritization Panel Editorial Board
Six experts from different
European countries and
selected for their experience
in horizon scanning
Seven representatives from
different European
countries
Anne-Florence Fay (CEDIT –
France)
Claudia Wild (Editor in Chief,
Austria)
Claire Parker (NHSC –
England)
Sue Simpson (Deputy Editor
in Chief, England)
Claudia Wild (LBI-HTA –
Austria)
Karla Douw (Denmark)
In˜aki Gutie´rrez (Osteba– the
Basque Country)
Sun Lee Hae Robin (France)
Inger Norderhaug (NOKC –
Norway)
In˜aki Gutie´rrez (the Basque
Country)
Sun Lee Hae Robin (HAS –
France)
Minna Kaila (Finland)
Collation of Results
Results were recorded and combined to help determine the
potential impact and rank of each health technology. Scores
from each panel member were added to give a possible total
of ten from part B and five from part C for each technology.
In part B, a score of 0 to 3 indicated a potentially low impact
technology, 4 to 6 indicated a potentially important tech-
nology, and 7 to 10 indicated a potentially highly significant
technology. In part C a score of: 5 indicated a technology that
should be considered a Type 1 technology for the newsletter,
4 indicated a technology that should be considered a Type 2
technology for the newsletter, 3 indicated a technology that
should be considered a Type 3 technology for the newsletter,
and 0 indicated that the technology should not be included in
the newsletter. Individual member’s scores were combined
for each technology and averaged. The average scores for
all of the health technologies listed in the spreadsheet were
reviewed together to determine which technologies should
be considered for the newsletter and for what type of arti-
cle. The results were sent to an editorial board (Box 2) for
their views on which technologies should be included in the
newsletter based on the information provided.
Production of the Newsletter
After the health technologies to be included in the newslet-
ter had been selected and the technology types were agreed
on, writing of the articles commenced. For each article,
this involved referring to the original entry in the EuroScan
database, searching the World Wide Web for more recent in-
formation, checking commercial databases (e.g., PharmaPro-
jects, Adis, etc) for the latest activities on pharmaceuticals,
searching bibliographic databases (e.g., MEDLINE) for re-
cent publications, and in some cases contacting the origi-
nal author of the EuroScan entry. Articles were written in
English.
RESULTS
Feedback on the Newsletter
The pilot newsletter and a questionnaire were sent to EU-
netHTA WP7 members with the request to distribute it to
decision makers (at least three) at the national, regional, and
local levels to reach a wide audience. The questionnaire was
sent to twenty-three EUnetHTA Associated Partners (April
7–May 30, 2007). They were asked to forward the ques-
tionnaire to two to three decision makers in their respective
countries. We asked for feedback on relevance, content, time-
liness, readability, and format of the newsletter. Forty (56
percent) answered. Responses were sent by people involved
in regulation, reimbursement, planning, research, and clinical
practice. Most respondents (85 percent) spoke English as a
second language. The majority found the newsletter relevant
(75 percent), agreed the newsletter contained information on
the potential effects of new technologies (75 percent), agreed
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Primary Sources 
β Medical engineering 
companies 
β Pharmaceutical  and 
biotechnological 
companies 
Secondary Sources 
β Key pharmaceutical 
journals 
β Specialist medical 
journals 
β Key medical journals 
β Private healthcare 
providers 
β Groups of healthcare 
Tertiary Sources 
β Newsletters and 
bulletins from other 
HTA agencies 
Primary Sources 
β Regulatory authorities 
(4 sources) 
β Societies of clinical 
oncology (incl. 
conference abstracts) (3 
sources) 
β Clinical trial registries 
(1 source) 
β Pharmaceutical 
companies (31 sources)
Secondary Sources 
β Newswires (medical 
and/ or oncology news) 
(10 sources) 
β  Medical journals (11    
sources) 
Tertiary Sources 
β HTA Agencies with 
existing HSS in 
oncology (3 sources) 
Example for Sources on Cancer Drugs 
Figure 1. Potential information sources and examples of categories of sources for cancer drugs (8; 17).
the articles were sufficiently up-to-date (87.5 percent), found
the text easy to understand (90 percent), and found the ar-
ticles clearly structured (92.5 percent). Fewer respondents
agreed that the articles focused on substantial issues (52.5
percent). Despite this positive response, several respondents
wanted more information about the effectiveness, cost effec-
tiveness, and potential impact of the technology. A substan-
tial criticism concerned timeliness, as several technologies
had already been introduced in the healthcare system be-
cause the technologies had been chosen for inclusion in the
newsletter. The first issue of On the Horizon, a newsletter
produced by EUnetHTA in collaboration with EuroScan and
the NHSC in England, was published in 2008 and presented
twelve technologies ranging from buccal insulin for dia-
betes to nicotine vaccines for smoking cessation (http://www.
eunethta.net/Communication/Newsletter_WP7_2008).
DISCUSSION
Future Identification and Priority Setting
Processes
The objective of EUnetHTA WP 7/B was to draw on the
experience and know-how of EuroScan to provide a Euro-
pean newsletter with early alerts on emerging or new health
technologies. The supposed added value to the EuroScan
members’ activities in scanning, identifying, collating data,
and producing early assessment papers would be the collec-
tion of information in a unique format and its wide distri-
bution by means of the EUnetHTA Partners. Two-thirds of
the then fifteen EuroScan members were involved in plan-
ning and designing the newsletter or commenting on it. De-
spite the seemingly facile intention, several obstacles had to
be faced. In comparison with the conclusions of Douw et
al. in 2006 (5) on priority setting methods used in horizon
scanning, it was concluded that the method for priority set-
ting developed for the EUnetHTA newsletter is now the only
formal priority setting method, or at least the only one pub-
lished in this field. What this method adds, as opposed to
an informal method, is that it addresses the same criteria
for each potentially significant technology, it measures these
criteria (i.e., major, moderate, minor impact), it scores the
criteria, and it uses the final score to determine if a technol-
ogy will be included in the newsletter (i.e., if it is prioritized).
Hence, the criteria are applied more consistently and more
transparently, which was Douw et al.’s major critique regard-
ing the current methods of selecting technologies in horizon
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scanning systems. A further increase in transparency and
consistency would, however, be achieved if the criteria could
be validated, which this project has not yet done. Those pri-
oritizing potentially significant new technologies appear to
have differing interpretations of what constitutes a “major
potential health benefit” as compared with a “moderate or
minor potential health benefit”. When national prioritization
exercises are undertaken, they often happen in a group set-
ting that allows experts to have an evolving discussion in
which their opinions might change toward consensus. In the
further development of a European-wide prioritization pro-
cess, a discussion forum might be an element to be added,
but it must be balanced against the possibility of losing trans-
parency.
An important issue for all services providing information
on new and emerging health technologies, and consequently
for a European newsletter, is whether the information com-
plements useful policy advice for the EU Member States
and meets the needs of the intended audience. EuroScan,
EUnetHTA, and InnoHTA (another EU project 2007/08) all
aimed to address uncertainty and the lack of sound infor-
mation in early stages of a technology. Although each has
made valuable contributions to the field of horizon scan-
ning, the issue of trading off certainty for being early re-
mains to be resolved in a methodologically sound way. The
question is whether this needs to be done in the context of
horizon scanning aimed only at providing early awareness
information. What may be more important in the context of
the EU-wide newsletter is whether the scope or objective
of the information service corresponds with the identified
technologies and those prioritized for assessment and later
disseminated.
The scope of this EUnetHTA Project was to inform about
“high volume, costly, and rapidly developing emerging health
technologies that are at an early stage of development and
which may have a significant impact on health care in the
EU.” The main source of new and emerging technologies to
fulfill this objective came from EuroScan member agencies
by means of the EuroScan database. EuroScan’s prioritiza-
tion criteria were used to select the technologies to be in-
cluded in the newsletter. As EuroScan members have a wide
range of customers and varying coverage, there would have
been some preselection/filtering, resulting in a list of selected
technologies for the newsletter that would differ from a list
derived through other sources. Although a possibility, it is
unlikely that EuroScan would miss any major technological
development that could impact on European health systems
because it includes fifteen member agencies from all regions
in the Western world (with diverse audiences and broadly
inclusive coverage systems). However, for an EU-wide in-
formation service to respond to the needs of all EU Member
States, any future project would need to investigate whether
the original objective actually reflects the preferences of all
EU Member States, including high, middle-, and low-income
countries.
CONCLUSIONS AND RECOMMENDATIONS
The intent of EUnetHTA WP7/B was to develop an EU-wide
newsletter on new and emerging health technologies. Be-
cause such a newsletter would be highly visible and have
the potential to impact on agenda setting throughout Europe,
considerable effort was put into developing transparent pro-
cesses to select topics for the newsletter and to involve a wide
range of European HTA experts in the prioritization process.
However, less attention was given to the specific informa-
tion needs of the intended audience. Feedback on the pilot
newsletter (forty respondents from ten European countries)
made it obvious that users of the newsletter lacked under-
standing of what kind of information is available in the early
stages of a health technology’s development; they wanted
more information than could be provided on cost effective-
ness, licensing, etc. We found that the ambitions of what
can be provided and the illusion of what can be achieved by
early information must be articulated explicitly and honestly.
The essential discussions of “value for money,” “maximizing
health gain,” or “societal value” definitely overload the idea
of “alerting” about emerging technologies.
Second, the audience had very diverse interests, for ex-
ample, some wanting information only on devices, others
on pharmaceuticals. Third, the practicality of EU-wide in-
volvement of experts for scoring and prioritization was a
time-consuming process that is difficult to organize in the
present international constellation of EAASs and hinders the
production of timely information. The aim of wider dissem-
ination of information on new and emerging technologies
remains, but the methods for doing this in a way that satisfies
intended audiences need further development.
Two options might be pursued to collaboratively estab-
lish an EU newsletter on new and emerging health technolo-
gies. The first would be to investigate the various interests
through a consensus method involving representatives of all
relevant EU Member States: An electronic information ser-
vice “on-demand” might be a solution closer to the actual
needs. The second would be to pursue EuroScan’s earlier
idea of developing a core set of early awareness information
on technologies in a database (e.g., derived from EuroScan’s
database) to help HTA agencies in EU Member States de-
velop early assessments fitting to their specific jurisdictions.
In any case, sharing information on emerging and new health
technologies remains a top priority for collaboration.
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